Bijender Kumar

Leukemia and NK CAR Scientist in @lab_rezvani at MD Anderson Cancer Center & a proud aiimsonian.

[Bijender Kumar @Bijender2050]

@HindRafei @lab_rezvani @abhinavjain_phd Congratulations @HindRafei and @lab_rezvani . We all are incredibly proud of you @HindRafei . The sheer grit and hard work you have put in for this story over the last 3-4 years is really commendable. I am really fortunate to witness this closely.

[Katy Rezvani, M.D., Ph.D @lab_rezvani]

Please check out our paper published in @NatureMedicine on our Phase I trial of AFM13-precomplexed cord blood NK cells in relapsed/refractory CD30+ lymphomas. Led by Dr. Yago Nieto and an outstanding team of coauthors and collaborators, this study marks the first clinical demonstration of NK cell redirection using a bispecific engager. We report an ORR of 92.9% and CR of 66.7% in 42 patients with a median of 7 prior therapies and show that this approach is safe and may serve as a bridge to SCT. Excited to move forward with our next generation engineered NK cells in combination with engagers and mAbs. #CancerResearch #Immunotherapy #NKcells @MDAndersonNews

[Bijender Kumar @Bijender2050]

@CollaSimona @may_daher @SpringerNature @NatureComms Always a team effort! Thank you for considering me for this exciting project n looking forward to It's clinical translation!

[May Daher @may_daher]

This will be an amazing symposium for those interested in myeloid malignancies. Checkout the exciting program organized by @CollaSimona ! I will be presenting some of our work on NK cell epigenetic scarring in MDS and AML. @MDAndersonNews #MDS #AML #NK

[Bijender Kumar @Bijender2050]

@jayastuMD @AjHematology @Daver_Leukemia @FadiHaddad_MD @NicholasShortMD @MrinalPatnaik @Dr_AmerZeidan @TalhaBadarMD @Anand_88_Patel @MathewsVikram @akhilrk1989 @grichardmd Congratulations @jayastuMD

[Katy Rezvani, M.D., Ph.D @lab_rezvani]

Thank you, Dr. Pisters for your inspiring vision. Our team of dedicated scientists and clinicians is committed to advancing cell therapies that will bring transformative treatments to patients with cancer, autoimmune disorders and infection diseases @MDAndersonNews #CellTherapy #endcancer

[Bijender Kumar @Bijender2050]

@rftbsr9 @ScienceTM @may_daher @lab_rezvani Thank you Rafet. Congratulations to you as well .

[Bijender Kumar @Bijender2050]

Excited to share our new publication in @ScienceTM. Incredibly proud of my AML buddy @may_daher for shaping this project. Thanks a ton to our amazing mentor @lab_rezvani for her never ending support and guidance that has been a pivotal part of my professional journey.

[May Daher @may_daher]

Excited to share our manuscript published in @ScienceTM, where we describe a novel NK immune evasion strategy in AML. We found that #BATF is a key transcription factor driving epigenetic reprogramming in NK cells in AML. This TF is induced by the canonical TGF-β/SMAD pathway and leads to persistent NK cell dysfunction. This dysfunction can be prevented by deleting BATF or TGFBR2 upstream, but once established, it cannot be reversed. Designed to overcome epigenetic scarring, we look forward to bringing this novel CAR-NK cell approach to the clinic to improve outcomes for AML patients. @mdandersonnews @lab_rezvani @bijender2050 #AML #NK #CRISPR #epigenetics #BATF

[Bijender Kumar @Bijender2050]

@lab_rezvani @may_daher @ScienceTM Dear Dr. Rezvani, thank you so much for your faith in me and being there always !

[Bijender Kumar @Bijender2050]

@HindRafei @may_daher @lab_rezvani @MDAndersonNews Thank you Hind 🙏

[May Daher @may_daher]

Excited to share our manuscript published in @ScienceTM, where we describe a novel NK immune evasion strategy in AML. We found that #BATF is a key transcription factor driving epigenetic reprogramming in NK cells in AML. This TF is induced by the canonical TGF-β/SMAD pathway and leads to persistent NK cell dysfunction. This dysfunction can be prevented by deleting BATF or TGFBR2 upstream, but once established, it cannot be reversed. Designed to overcome epigenetic scarring, we look forward to bringing this novel CAR-NK cell approach to the clinic to improve outcomes for AML patients. @mdandersonnews @lab_rezvani @bijender2050 #AML #NK #CRISPR #epigenetics #BATF

[Bijender Kumar @Bijender2050]

@romeerizwan @lab_rezvani It was great meeting you in person finally and learn more about group’s amazing research on CIMK NK. Way to go!

[David S. Hong MD @DavidHongMD]

The future of cell therapy! CAR NK! @MDAndersonNews

[Hind Rafei @HindRafei]

Tour de force presentation today by Dr. Katy Rezvani @lab_rezvani at the Allison Institute @MDAndersonNews encompassing great science and a proliferative pipeline of cell therapies for our patients with heme and solid cancers! #NK #celltherapy

[Bijender Kumar @Bijender2050]

@rftbsr9 @ESHaematology Wonderful! Congratulations @rftbsr9

[Springer Pathology @SpringerPath]

Increased expression of CD70 in relapsed acute myeloid leukemia after hypomethylating agents https://t.co/uWuCfln2hE

[UT MD Anderson @UTMDAnderson]

Our Dr. Katy Rezvani, recipient of @ASH_hematology’s 2023 Honorific Award, delivers the E. Donnall Thomas Lecture at #ASH23 on Natural Killer Cells: A New Frontier for Cancer Immunotherapy.

We’re grateful for her pioneering contributions to this innovative field and her commitment to #EndCancer. @lab_rezvani

[Katy Rezvani, M.D., Ph.D @lab_rezvani]

Thank you very much Dr. Brodsky @DocsDock200 for your very kind words! It was such an honor to receive this award from ASH. Please accept my sincere congratulations for presiding over such an amazing #ASH23 @MDAndersonNews